Speaking of biotech being lucrative
People are still pouring money into biotech venture capital.
The latest evidence comes from Omega Funds, the Boston-based VC that just raised $438 million, as STAT’s Kate Sheridan reports. That makes for Omega’s biggest fund to date, and it follows a trend of biotech VCs raising more money, more often amid escalating demand from the pensions and family offices that front the cash.
Meanwhile, the pace of investment has followed suit. Biotech was the No. 1 sector in terms of VC deals last quarter, according to PwC, and three of the five biggest funding rounds went to companies developing drugs.
Read more.
The latest evidence comes from Omega Funds, the Boston-based VC that just raised $438 million, as STAT’s Kate Sheridan reports. That makes for Omega’s biggest fund to date, and it follows a trend of biotech VCs raising more money, more often amid escalating demand from the pensions and family offices that front the cash.
Meanwhile, the pace of investment has followed suit. Biotech was the No. 1 sector in terms of VC deals last quarter, according to PwC, and three of the five biggest funding rounds went to companies developing drugs.
Read more.
.png)
No hay comentarios:
Publicar un comentario